+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904951
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The lung cancer therapeutics market is shaped by rapid clinical and technological advances, pushing senior leaders to balance innovation and operational responsiveness to maintain a strategic edge in an evolving healthcare environment.

Market Snapshot: Lung Cancer Therapeutics Market Overview

The lung cancer therapeutics market demonstrated robust expansion, growing from USD 30.70 billion in 2024 to USD 33.23 billion in 2025, and is projected to attain USD 59.89 billion by 2032 with a CAGR of 8.70%. This trajectory underscores a dynamic landscape where opportunities proliferate in drug development, advanced diagnostics, and novel delivery systems. This growth invites senior executives to refine commercialization routes and patient-centric models, leveraging innovation while balancing competitive dynamics. In this context, sustained market relevance depends on clear value differentiation and strong cross-functional execution across R&D, regulatory, and market access functions.

Scope & Segmentation: Modalities, Categories, and Regional Perspectives

  • Therapy Categories: Chemotherapy, immunotherapy, radiation therapy, and targeted therapy each present unique clinical implications and shape product pipelines. Portfolio planning must consider evolving clinical standards and emerging competitive benchmarks.
  • Administration Modalities: Inhalation, injectable, and oral administration approaches allow for alignment with patient adherence goals, broadening flexibility in treatment algorithms and resource allocation.
  • Histology Distinctions: Non-small cell and small cell lung cancer require tailored therapeutic and regulatory strategies due to distinct biological profiles and treatment guidelines.
  • Line of Therapy: Strategies span adjuvant, neoadjuvant, first-line, maintenance, second-line, and subsequent treatments—each impacting regulatory timelines and clinical trial design.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, specialty clinics, and digital platforms all play a role in patient access, reimbursement patterns, and the scope of market penetration.
  • Geographic Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific regions each contribute distinct regulatory, infrastructure, and payer realities, guiding regional business models and adaptation strategies.
  • Technologies: Molecular diagnostics, biomarker-driven therapy selection, and digital engagement tools enable targeted treatment and support scalable patient management, fundamentally shifting market and clinical operations.

Lung Cancer Therapeutics Market: Key Takeaways for Senior Leaders

  • Multi-modality regimens that integrate immuno-oncology and targeted approaches are establishing new care models and influencing cross-sector collaboration.
  • Detailed segmentation by histology and therapy line supports accelerated development and positioning of differentiated products within crowded pipelines.
  • Adoption of patient-centered delivery systems and digital support solutions is increasing adherence and optimizing real-world therapy outcomes.
  • Enhanced partnerships among pharmaceutical, clinical, and diagnostic sectors streamline biomarker testing, supporting timely patient identification and access to therapy.
  • Regional adaptation in clinical, manufacturing, and distribution strategies is vital as regulatory and payer landscapes shift more rapidly, demanding organizational agility for timely market entry.

Tariff Impact: Navigating Trade and Manufacturing Disruptions

Fluctuations in tariffs and import duties are adding operational complexity across the lung cancer therapeutics supply chain. To address these cost and continuity challenges, manufacturers are expanding regional production capabilities and incorporating redundant supply solutions. Flexible contracting and new biologic manufacturing investments reduce risk, while tighter partnerships with domestic providers help secure reliable delivery channels and future-proof next-generation therapies. These measures promote resilience as companies navigate ongoing global trade uncertainties.

Methodology & Data Sources

This analysis integrates structured interviews with clinical investigators, regulatory specialists, supply chain managers, and payers. Findings are grounded in peer-reviewed studies, regulatory reports, and outcomes from clinical trials. Rigorous cross-validation and robust scenario planning ensure that conclusions are actionable and ethically sound for decision-making.

Why This Report Matters for the Lung Cancer Therapeutics Market

  • Offers senior leaders a comprehensive perspective merging commercial, clinical, and operational drivers to optimize enterprise strategies in the lung cancer therapeutics space.
  • Supports development of agile supply chain and payer engagement initiatives to sustain growth and navigate shifting market challenges effectively.
  • Presents actionable segmentation insights and identifies levers for sustainable market success amid evolving therapy platforms and regional dynamics.

Conclusion: Aligning Innovation and Execution in Lung Cancer Therapeutics

Leaders who align clinical progress, operational strength, and payer engagement can expand access and secure organizational relevance as the therapeutics landscape advances. Strategic adoption of these targeted market insights supports informed, future-focused decision-making.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2024
3.5. FPNV Positioning Matrix, 2024
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Lung Cancer Therapeutics Market, by Therapy Type
8.1. Chemotherapy
8.1.1. Alkylating Agents
8.1.2. Platinum-Based
8.1.3. Taxanes
8.1.4. Topoisomerase Inhibitors
8.2. Immunotherapy
8.2.1. CTLA-4 Inhibitors
8.2.2. PD-1 Inhibitors
8.2.3. PD-L1 Inhibitors
8.3. Radiation Therapy
8.3.1. Brachytherapy
8.3.2. External Beam Radiation
8.3.3. Stereotactic Body Radiation
8.4. Supportive Care
8.4.1. Antiemetics
8.4.2. Bone-Modifying Agents
8.4.3. Hematopoietic Growth Factors
8.5. Surgery
8.6. Targeted Therapy
8.6.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
8.6.2. BRAF Inhibitors
8.6.3. EGFR Inhibitors
9. Lung Cancer Therapeutics Market, by Mode Of Administration
9.1. Inhalation
9.2. Injectable
9.3. Oral
10. Lung Cancer Therapeutics Market, by Line Of Therapy
10.1. First-Line
10.2. Second-Line
10.3. Third-Line & Beyond
11. Lung Cancer Therapeutics Market, by Disease Stage
11.1. Stage I
11.2. Stage II
11.3. Stage III
11.4. Stage IV
12. Lung Cancer Therapeutics Market, by Prescription Status
12.1. Branded
12.2. Generic
13. Lung Cancer Therapeutics Market, by Distribution Channel
13.1. Offline Retail
13.2. Online Retail
14. Lung Cancer Therapeutics Market, by Cancer Type
14.1. Non-Small Cell Lung Cancer (NSCLC)
14.1.1. Adenocarcinoma
14.1.2. Large Cell Carcinoma
14.1.3. Squamous Cell Carcinoma
14.2. Small Cell Lung Cancer (SCLC)
15. Lung Cancer Therapeutics Market, by End User
15.1. Ambulatory Infusion Centers
15.2. Cancer Centers
15.3. Homecare Settings
15.4. Hospitals
16. Lung Cancer Therapeutics Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Lung Cancer Therapeutics Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Lung Cancer Therapeutics Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Lung Cancer Therapeutics Market
20. China Lung Cancer Therapeutics Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2024
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2024
21.3. Product Portfolio Analysis, 2024
21.4. Benchmarking Analysis, 2024
21.5. AbbVie Inc.
21.6. Amgen Inc.
21.7. Astellas Pharma Inc.
21.8. AstraZeneca PLC
21.9. Bayer AG
21.10. Boehringer Ingelheim International GmbH
21.11. Johnson & Johnson Services, Inc.
21.12. Merck & Co., Inc.
21.13. Novartis AG
21.14. Pfizer Inc.
21.15. Sanofi S.A
21.16. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 126. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY REGION, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 162. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 163. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 165. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 166. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 214. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 215. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 216. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 217. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 218. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 219. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 221. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 222. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 223. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 225. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 226. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 229. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 231. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 232. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 233. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 234. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 236. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 237. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 238. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 240. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 241. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 243. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 244. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 245. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 246. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 247. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 248. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 249. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 250. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 251. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 252. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 253. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 255. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 256. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 260. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 261. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 262. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 263. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 264. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 266. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 267. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 268. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 269. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 270. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 271. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 273. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 275. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 276. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 277. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 278. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 279. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 280. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 281. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 282. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 283. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 284. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 285. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 286. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 287. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 288. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 289. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 290. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 291. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 292. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
TABLE 293. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 294. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 295. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 296. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 297. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 298. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 299. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 300. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 301. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
TABLE 302. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION

Companies Mentioned

The key companies profiled in this Lung Cancer Therapeutics market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • Cullinan Therapeutics, Inc.
  • Daiichi Sankyo, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Innovent Biologics (Suzhou) Co., Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • MAIA Biotechnology, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Nuvalent, Inc.
  • OS Therapies Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A
  • Shanghai Henlius Biotech, Inc.
  • Summit Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedJanuary 2026
Forecast Period2025 - 2032
Estimated Market Value ( USD ) in 2025 $ 33.23 Billion
Forecasted Market Value ( USD ) by 2032 $ 59.89 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Lung Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Lung Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Lung Cancer Treatment Market - Global Strategic Business Report - Product Image

Lung Cancer Treatment Market - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032 - Product Image

Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2025 - Product Image

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F - Product Image

Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.